11.25

1.08% 0.12

After Hours: 11.13 -0.12 -1.07%

Kura Oncology Inc (KURA)

Overview News Price History Option Chain Financials Discussions Forecast

Kura Oncology Inc stock is traded at $11.25, with a volume of 2.49M. It is up +1.08% in the last 24 hours and up +18.05% over the past month. Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Previous Close:

$11.13

Open:

$11.12

24h Volume:

2.49M

Relative Volume:

1.59

Market Cap:

$998.71M

Revenue:

$67.48M

Net Income/Loss:

$-278.67M

P/E Ratio:

-3.5406

EPS:

-3.1774

Net Cash Flow:

$-70.70M

1W Performance:

+22.02%

1M Performance:

+18.05%

6M Performance:

+0.72%

1Y Performance:

+80.29%

1-Day Range:

$11.01

$11.52

1-Week Range:

$8.95

$11.52

52-Week Range:

$5.45

$12.49

Kura Oncology Inc Stock (KURA) Company Profile

Name

Kura Oncology Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(858) 500-8800

Address

4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA

Employee

260

Twitter

@kuraoncology

Next Earnings Date

2026-05-12

Latest SEC Filings

KURA's Discussions on Twitter

Compare KURA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KURA Kura Oncology Inc	11.25	988.06M	67.48M	-278.67M	-70.70M	-3.1774
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Lake Street	Buy
Sep-04-25	Initiated	Guggenheim	Neutral
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy
Oct-14-24	Downgrade	Stifel	Buy → Hold
Dec-22-23	Initiated	Mizuho	Buy
Aug-11-23	Initiated	BofA Securities	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
May-17-23	Initiated	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight
Feb-15-22	Initiated	Jefferies	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Dec-07-20	Reiterated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform
May-05-20	Initiated	Barclays	Overweight
Jul-18-19	Initiated	Deutsche Bank	Buy
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy
Oct-13-16	Resumed	Leerink Partners	Outperform
Jan-22-16	Initiated	JMP Securities	Mkt Outperform
Dec-30-15	Initiated	Oppenheimer	Outperform
Dec-16-15	Initiated	Citigroup	Buy

View All

Kura Oncology Inc Stock (KURA) Latest News

May 24, 2026

Kura Oncology’s SWOT analysis: biotech stock faces launch test By Investing.com - Investing.com India

May 24, 2026

Kura Oncology’s SWOT analysis: biotech stock faces launch test - Investing.com UK

May 24, 2026

May 22, 2026

KURA (NASDAQ: KURA) files Form 144 reporting proposed sale of 10,000 RSUs - Stock Titan

May 21, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 21, 2026

May 20, 2026

Kura Oncology COO Kathleen Ford sells $20,482 in stock By Investing.com - Investing.com South Africa

May 20, 2026

Insider Sell: Brian Powl Sells Shares of Kura Oncology Inc (KURA) - GuruFocus

May 20, 2026

Kura Oncology COO Kathleen Ford sells $20,482 in stock - Investing.com

May 20, 2026

Kathleen Ford Sells 2,257 Shares of Kura Oncology Inc (KURA) - GuruFocus

May 20, 2026

Kura Oncology (KURA) CCO sells 339 shares while retaining 183,614 - Stock Titan

May 20, 2026

Kura Oncology (KURA) COO sells 2,257 shares under pre-set trading plan - Stock Titan

May 20, 2026

[Form 4] Kura Oncology, Inc. Insider Trading Activity - Stock Titan

May 20, 2026

KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill

May 20, 2026

May 19, 2026

[144] Kura Oncology, Inc. SEC Filing - Stock Titan

May 19, 2026

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit - The Manila Times

May 19, 2026

Virtual oncology fireside chat: Kura Oncology joins TD Cowen summit - Stock Titan

May 19, 2026

Kura Oncology Q1 earnings call highlights - MSN

May 19, 2026

May 18, 2026

Kura Oncology’s SWOT analysis: stock faces launch challenges despite FDA approval - Investing.com UK

May 18, 2026

Kura Oncology’s SWOT analysis: biotech stock faces launch challenges - Investing.com

May 18, 2026

Kura Oncology’s SWOT analysis: biotech stock faces launch challenges By Investing.com - Investing.com Nigeria

May 18, 2026

Earnings call transcript: Kura Oncology Q1 2026 revenue miss overshadows stable EPS - Investing.com UK

May 18, 2026

May 17, 2026

Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates - Yahoo Finance

May 17, 2026

Kura Oncology stock (US50126D1028): FDA breakthrough nod and pipeline update draw investor focus - AD HOC NEWS

May 17, 2026

May 16, 2026

LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo

May 16, 2026

UBS Group AG Acquires 574,455 Shares of Kura Oncology, Inc. $KURA - MarketBeat

May 16, 2026

Kura Oncology (NASDAQ:KURA) Rating Increased to Hold at Wall Street Zen - MarketBeat

May 16, 2026

May 15, 2026